AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Immuneering Corp Director's Dealing 2024

Feb 9, 2024

32973_dirs_2024-02-09_82096193-a6e2-447c-bcb9-b7e90dfefd70.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Immuneering Corp (IMRX)
CIK: 0001790340
Period of Report: 2024-02-08

Reporting Person: Neufeld Leah R (CHIEF PEOPLE OFFICER)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-02-08	Stock Option	$6.09	A	60500	Acquired	2034-02-08	Class A Common Stock (60500)	Direct

Footnotes

F1: The option vests and becomes exercisable in equal monthly installments over a four-year period commencing on February 1, 2024, and will be fully vested and exercisable on January 1, 2028.